Breast Cancer: Breast cancer is second only to lung cancer as the leading cancer cause of death in women. In 2010 207,000 women will be diagnosed with breast cancer and over 39,000 are expected to die from breast cancer. Nevertheless, ongoing research and recent advances in both diagnostic and therapeutic modalities continue to make breast cancer management a rapidly evolving area in which the practitioner will want to be fully updated on current developments. Breast Cancer offers a comprehensive and in-depth review of the current literature of breast cancer. Chapters examine risk factors and prevention strategies, trends and developments in imaging, surgical management, radiotherapy advances, adjuvant endocrine and chemotherapies, targeted metastatic therapy, and the role of bisphosphonates and novel bone agents in breast cancer. With this volume the oncology practitioner will have a full and current overview of all significant current trends in this important area of oncology. About the Series: Emerging Cancer Therapeutics is an invited review publication providing a through analysis of key clinical research related to cancer therapeutics, including a discussion and assessment of current evidence, current clinical best practice, and likely near future developments. There is an emphasis throughout on multidisciplinary approaches to the specialty, as well as on quality and outcomes analysis. Published three times a year Emerging Cancer Therapeutics provides authoritative, thorough assessments of advances in therapeutics in all major areas of oncology, both solid and hematologic malignancies, with a focus on advances in medical and biological therapies with emerging clinical impact and encompassing new technologies with implications for management such as molecular imaging. Features of Emerging Cancer Therapeutics include: Editorial board of nationally recognized experts across the spectrum of Cancer Therapeutics In-depth, up-to-date expert reviews and analysis of major new developments in all areas of Cancer Therapeutics Issues edited by an authority in specific subject area Focuses on major topics in Cancer Therapeutics with in-depth articles covering advances in clinical and translational research developments, as well as clinical applications and experience Emphasizes multidisciplinary approaches to research and practice

Breast Cancer:

Breast cancer is second only to lung cancer as the leading cancer cause of death in women. In 2010 207,000 women will be diagnosed with breast cancer and over 39,000 are expected to die from breast cancer.

Nevertheless, ongoing research and recent advances in both diagnostic and therapeutic modalities continue to make breast cancer management a rapidly evolving area in which the practitioner will want to be fully updated on current developments.

Breast Cancer offers a comprehensive and in-depth review of the current literature of breast cancer. Chapters examine risk factors and prevention strategies, trends and developments in imaging, surgical management, radiotherapy advances, adjuvant endocrine and chemotherapies, targeted metastatic therapy, and the role of bisphosphonates and novel bone agents in breast cancer. With this volume the oncology practitioner will have a full and current overview of all significant current trends in this important area of oncology.

About the Series:

Emerging Cancer Therapeutics is an invited review publication providing a through analysis of key clinical research related to cancer therapeutics, including a discussion and assessment of current evidence, current clinical best practice, and likely near future developments. There is an emphasis throughout on multidisciplinary approaches to the specialty, as well as on quality and outcomes analysis. Published three times a year Emerging Cancer Therapeutics provides authoritative, thorough assessments of advances in therapeutics in all major areas of oncology, both solid and hematologic malignancies, with a focus on advances in medical and biological therapies with emerging clinical impact and encompassing new technologies with implications for management such as molecular imaging.

Features of Emerging Cancer Therapeutics include:

• Editorial board of nationally recognized experts across the spectrum of Cancer Therapeutics
• In-depth, up-to-date expert reviews and analysis of major new developments in all areas of Cancer Therapeutics
• Issues edited by an authority in specific subject area
• Focuses on major topics in Cancer Therapeutics with in-depth articles covering advances in clinical and translational research developments, as well as clinical applications and experience
• Emphasizes multidisciplinary approaches to research and practice

1. Risk Factors and Strategies for Prevention of Breast CancerSameh Mikhail andJennifer Eng-Wong, 2. Current Trends and New Developments in Breast Cancer ImagingLilian C. Wang, Paula Grabler, Mariana Solari, Sandra S. Rao, andPatricia J. Karstaedt, 3. Update on the Surgical Management of Breast Cancer: Areas of Controversy and AdvancementFatema Al-Mushawah andRebecca Aft, 4. Advances in Radiotherapy for Breast CancerSharad Goyal, Atif J. Khan, andBruce G. Haffty, 5. Adjuvant Chemotherapy for Breast Cancer: Updates and New PerspectivesConleth G. Murphy, Clifford A. Hudis, andHeather L. McArthur, 6. Endocrine Therapy for Early Breast CancerMary Cianfrocca, 7. HER2-Targeted Treatment in the Adjuvant Setting for Breast CancerSerena T. Wong andAntoinette R. Tan, 8. Endocrine Treatment for Metastatic Breast CancerShamsuddin Virani andJame Abraham, 9. Chemotherapy for Metastatic Breast CancerHamid R. Mirshahidi andJame Abraham, 10. Targeted Therapy for Metastatic Breast CancerAmelia B. Zelnak andRuth OÌRegan, 11. Management of HER2-Positive Metastatic Breast Cancer: Standard and New ApproachesNabila Chowdhury and Sandra M. Swain, 12. Treatment Options for Triple-Negative Breast CancerKatherine Enright andRebecca Dent, 13. The Expanding Role of Bisphosphonates and Novel Bone Agents in Breast CancerLarissa A. Korde andJulie R. Gralow, 14. Principles of Breast Cancer GenomicsOlivier D. Loudig andJoseph A. Sparano